Clinical trials: Oral Phase
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy Adult Participants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need.
- Trial name
- NCT05735249
- Testing
- ARN-75039 oral capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Arisan Therapeutics, Inc.
Healthy
[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study
[14C]PRC-4016 (Icosabutate) - A Phase I, Open-Label Study of the Absorption, Metabolism and Excretion Following Oral Dosing to Healthy Male Subjects.
- Trial name
- NCT02373176
- Testing
- [14C]PRC 4016 (Icosabutate)
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pronova BioPharma
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Oral Mucositis
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
The purpose of this study is to determine whether an oral rinse composed of botanical extracts is effective in the prevention of severe inflammation of the lining of the oral cavity caused by chemotherapy and radiation therapy…
- Trial name
- NCT01400620
- Testing
- IZN-6N4
- Where
- 10 sites in United States, Israel
- Volunteers
- 110 people
- Sponsor
- Izun Pharma Ltd
Healthy
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets
This is a Phase 1 Relative Bioavailability Study Comparing The Pharmacokinetics Of Aramchol Meglumine (AM) Granules For Oral Suspension To Aramchol Free Acid (AA) 300 mg Tablets In Healthy Volunteers
- Trial name
- NCT06502561
- Testing
- Aramchol meglumine, Aramchol free acid
- Where
- Bulgaria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Galmed Pharmaceuticals Ltd
Sjogren Disease
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
- Trial name
- EnVISage (NCT06928142)
- Testing
- Sibeprenlimab
- Where
- 64 sites in United States, Argentina and 6 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Solid Tumor
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene…
- Trial name
- NCT03834220
- Testing
- Debio 1347
- Where
- 105 sites in United States, Australia and 21 more
- Volunteers
- 63 people
- Sponsor
- Debiopharm International SA
Healthy
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
The sponsor wants to investigate in this study how well the test medicine is taken up by the body when given orally (by mouth) as a tablet and solution, and as a solution for infusion (into a vein).
- Trial name
- NCT04136327
- Testing
- GLPG1972 film-coated tablets, [14C]-GLPG1972 solution for infusion, [14C]-GLPG1972 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Healthy Volunteers, Schizophrenia
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of TAK-041: 1. Following oral single and multiple doses in healthy participants. 2.
- Trial name
- NCT02748694
- Testing
- TAK-041
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
Healthy Participants
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
- Trial name
- NCT07412288
- Testing
- KT-579
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Healthy Volunteers
Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects
This study is a phase I, randomized, placebo-controlled, double-blind (sponsor unblind), three part study. The primary objective of the study is to characterize the safety, and tolerability of GSK3008356 single dose, 14 daily…
- Trial name
- NCT02742766
- Testing
- GSK3008356
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Oral Mucositis, Head and Neck Cancer
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug or radiation regiments used to treat cancer. This study examines the investigational drug SCV-07 and it's possible application in treating Oral…
- Trial name
- SCV-07 OM (NCT00756951)
- Testing
- SCV-07
- Where
- 19 sites in United States
- Volunteers
- 59 people
- Sponsor
- SciClone Pharmaceuticals
Gastro Esophageal Reflux Disorder
Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers
A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult…
- Trial name
- NCT07727629
- Testing
- UI059, UIC202201
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Parkinson Disease
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered…
- Trial name
- LoCaMoTE-PD (NCT07005180)
- Testing
- HBI-002
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.